Ge vct scanner

Before the screening procedure, each patient underwent MRI for evaluating the size of and staging the recurrent tumor. At our hospital, a GE VCT scanner (GE Medical Systems, Milwaukee, WI, USA) is used for PET/CT scanning. In this trial, whole-body ¹⁸F-fluorodeoxyglucose (FDG)-PET/CT was conducted to rule out distant metastases. The ¹⁸F-BPA-PET/CT procedure was repeated before BNCT to derive T/N ratios. The injected dose of ¹⁸F-BPA was approximately 5 mCi. ¹⁸F-BPA uptake in the tumor was measured by calculating the mean standard uptake value (SUV) for the GTV. ¹⁸F-BPA uptake in the normal tissue was measured by calculating the mean SUV for a region in the subcutaneous connective tissue on the contralateral side of the GTV; this measurement was conducted 60 min after ¹⁸F-BPA injection.

The ⁶⁴Cu-copper-II-diacetyl-bis(N4-methylthiosemicarbazone) (⁶⁴Cu-ATSM) PET computed tomography (CT) scans were acquired a week before the surgery on a PET/CT GE VCT scanner (General Electric Medical Systems, Waukesha, WI, USA) with 500-mm axial field of view (FOV) and spatial resolution of 6-mm full-width-at-half-maximum (FWHM) [23 (link)]. Subjects were scanned in fasting state and positioned supine, arms down wi th knee support such that the tumour site was in the centre of the FOV. Administered was 600 MBq of ⁶⁴Cu-ATSM, a putative marker of tissue hypoxia, followed by a low-dose CT scan and a 10-min PET scan 70 min post-injection. The patient’s head was fixed firmly but comfortably to minimise movement during the PET-CT scan using the standard scanner headrest. Five out of six PET data sets were reconstructed using the three-dimensional (3D) re-projection algorithm and one data set using the proprietary GE 3D-‘Viewpoint’ algorithm. All PET images were corrected for radioactive decay and attenuation corrected using CT.